These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 9859750)

  • 41. Effect of verapamil in intermittent claudication.
    Switzer DS
    J Fam Pract; 1997 Apr; 44(4):337. PubMed ID: 9108822
    [No Abstract]   [Full Text] [Related]  

  • 42. An analysis of relationship between quality of life indices and clinical improvement following intervention in patients with intermittent claudication due to femoropopliteal disease.
    Mazari FA; Carradice D; Rahman MN; Khan JA; Mockford K; Mehta T; McCollum PT; Chetter IC
    J Vasc Surg; 2010 Jul; 52(1):77-84. PubMed ID: 20471779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
    Kieffer E; Bahnini A; Mouren X; Gamand S
    Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does percutaneous transluminal angioplasty improve quality of life?
    Keeling AN; Naughton PA; O'Connell A; Lee MJ
    J Vasc Interv Radiol; 2008 Feb; 19(2 Pt 1):169-76. PubMed ID: 18341944
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of disease impact in patients with intermittent claudication: discrepancy between health status and quality of life.
    Breek JC; de Vries J; van Heck GL; van Berge Henegouwen DP; Hamming JF
    J Vasc Surg; 2005 Mar; 41(3):443-50. PubMed ID: 15838478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of the efficacy of vasodilator drugs in peripheral vascular disease through a study of skeletal muscle metabolism using 31P nuclear magnetic resonance (NMR) spectroscopy.
    Wahl D; Simon JP; Escanye JM; Jouanny P; Robin B; Walker P; Paille F; Schmidt C; Robert J; Schmitt J
    Therapie; 1992; 47(2):125-6. PubMed ID: 1412138
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of intermittent claudication with inositol nicotinate.
    Head A
    Practitioner; 1986 Jan; 230(1411):49-54. PubMed ID: 3513149
    [No Abstract]   [Full Text] [Related]  

  • 48. Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial.
    Kiff RS; Quick CR
    Br J Clin Pract; 1988 Apr; 42(4):141-5. PubMed ID: 3061427
    [No Abstract]   [Full Text] [Related]  

  • 49. [On the conservative treatment of intermittent claudication].
    Brecht T; Hild R; Fux HD
    Munch Med Wochenschr; 1966 Dec; 108(48):2458-61. PubMed ID: 5340039
    [No Abstract]   [Full Text] [Related]  

  • 50. Assessing the validity and responsiveness of disease-specific quality of life instruments in intermittent claudication.
    Mehta T; Venkata Subramaniam A; Chetter I; McCollum P
    Eur J Vasc Endovasc Surg; 2006 Jan; 31(1):46-52. PubMed ID: 16226903
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Upper- versus lower-limb aerobic exercise training on health-related quality of life in patients with symptomatic peripheral arterial disease.
    Saxton JM; Zwierska I; Blagojevic M; Choksy SA; Nawaz S; Pockley AG
    J Vasc Surg; 2011 May; 53(5):1265-73. PubMed ID: 21215558
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cilostazol in NICE guideline.
    Bellmunt S; Roset PN; Escudero JR
    Heart; 2012 Jul; 98(14):1107; author reply 1107-8. PubMed ID: 22591736
    [No Abstract]   [Full Text] [Related]  

  • 53. Quality of life.
    Khaira HS
    Eur J Vasc Endovasc Surg; 1995 Nov; 10(4):510-1. PubMed ID: 7489226
    [No Abstract]   [Full Text] [Related]  

  • 54. Quality-of-life assessment in comparative therapeutic trials and causal structure considerations in peripheral occlusive arterial disease.
    Lehert P
    Pharmacoeconomics; 2001; 19(2):121-30. PubMed ID: 11284379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patient-reported outcome measures in patients with peripheral arterial disease: a systematic review of psychometric properties.
    Poku E; Duncan R; Keetharuth A; Essat M; Phillips P; Woods HB; Palfreyman S; Jones G; Kaltenthaler E; Michaels J
    Health Qual Life Outcomes; 2016 Nov; 14(1):161. PubMed ID: 27881127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A statistical consideration of CLAU-S: a disease specific questionnaire for the assessment of quality of life in patients with intermittent claudication.
    Spengel FA; Lehert P; Dietze S
    Vasa; 1998 Nov; 27(4):253. PubMed ID: 9859750
    [No Abstract]   [Full Text] [Related]  

  • 57. Naftidrofuryl in quality of life (NIQOL). A Belgian study.
    D'Hooge D; Lehert P; Clement DL
    Int Angiol; 2001 Dec; 20(4):288-94. PubMed ID: 11782694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Intermittent claudication and quality of life. Psychometric validation of the French version of the CLAU-S questionnaire].
    Boccalon H; Lehert P; Comte S
    J Mal Vasc; 2000 Apr; 25(2):98-107. PubMed ID: 10804390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Naftidrofuryl can enhance the quality of life in patients with intermittent claudication.
    Spengel F; Brown TM; Poth J; Lehert P
    Vasa; 1999 Aug; 28(3):207-12. PubMed ID: 10483329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Assessment of the quality of life of patients with peripheral vascular diseases].
    Wohlgemuth WA; Niechzial M; Nagel E; Bohndorf K
    Rofo; 2003 Feb; 175(2):169-75. PubMed ID: 12584614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.